GlaxoSmithKline and Abbott to start production in Ukraine
UK pharma giant GlaxoSmithKline (LSE: GSK) and the USA’s Abbott (NYSE: ABT) are considering launching production of their drugs in Ukraine at the facilities of Indar, one of Ukraine’s largest pharmaceutical producers, owned by the state.
According to Lyobov Vishnevskaya, head of Indar, the company will start cooperation with GSK and Abbott this year. There is a possibility that at the initial stage the Ukrainian company will specialize in packing of drugs, among which will be multiple vaccines, as well as drugs against tuberculosis and HIV, while later it may launch their full cycle of production.
Ukrainian media reports suggest that, in addition to GSK and Abbott, Indar plans to launch production of drugs for another global major, the name of which has not yet been disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze